Srinivasa Reddy Bonam

Dr. Srinivasa Reddy Bonam

Department of Applied Biology, Indian Institute of Chemical Technology, Hyderabad, India
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2019 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
Srinivasa Reddy BonamSrinivasa Reddy Bonam
Srinivasa Reddy Bonam
FWFengjuan Wang
Fengjuan Wang
Sylviane MullerSylviane Muller
Sylviane Muller

1 September 2017 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
Srinivasa Reddy BonamSrinivasa Reddy Bonam
Srinivasa Reddy Bonam
CPCharalambos D. Partidos
Charalambos D. Partidos
SMSampath Kumar Halmuthur M
Sampath Kumar Halmuthur M
Sylviane MullerSylviane Muller
Sylviane Muller

14 March 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
KSK. Swetha
K. Swetha
NKNiranjan Kotla
Niranjan Kotla
LTLakshmi Tunki
Lakshmi Tunki
AJArya Jayaraj
Arya Jayaraj
SBSuresh K. Bhargava
Suresh K. Bhargava
Rajendra KurapatiRajendra Kurapati
Rajendra Kurapati
Lipid nanoparticles (LNPs) have recently emerged as one of the most advanced technologies for the highly efficient in vivo delivery of exogenous mRNA, particularly for COVID-19 vaccine delivery. LNPs comprise four different lipids: ionizable lipids, helper or neutral lipids, cholesterol, and lipids attached to polyethylene glycol (PEG). In this review, we present recent the advances and insights for the design of LNPs, as well as their composition and properties, with a subsequent discussion on the development of COVID-19 vaccines. In particular, as ionizable lipids are the most critical drivers for complexing the mRNA and in vivo delivery, the role of ionizable lipids in mRNA vaccines is discussed in detail. Furthermore, the use of LNPs as effective delivery vehicles for vaccination, genome editing, and protein replacement therapy is explained. Finally, expert opinion on LNPs for mRNA vaccines is discussed, which may address future challenges in developing mRNA vaccines using highly efficient LNPs based on a novel set of ionizable lipids. Developing highly efficient mRNA delivery systems for vaccines with improved safety against some severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants remains difficult.

1 August 2021 in Journal of Controlled Release
Verified
Journal Article
Open access
NKNiranjan G. Kotla
Niranjan G. Kotla
Srinivasa Reddy BonamSrinivasa Reddy Bonam
Srinivasa Reddy Bonam
SRSwetha Rasala
Swetha Rasala
JWJitendra Wankar
Jitendra Wankar
RBRaghvendra A. Bohara
Raghvendra A. Bohara
Abhay PanditAbhay Pandit
Abhay Pandit
Hyaluronan (HA) is a naturally occurring non-sulfated glycosaminoglycan (GAG), cell-surface-associated biopolymer and is the key component of tissue extracellular matrix (ECM). Along with remarkable physicochemical properties, HA also has multifaceted biological effects that include but not limited to ECM organization, immunomodulation, and various cellular processes. Environmental cues such as tissue injury, infection or cancer change downstream signaling functionalities of HA. Unlike native HA, the fragments of HA have diversified effects on inflammation, cancer, fibrosis, angiogenesis and autoimmune response. In this review, we aim to discuss HA as a therapeutic delivery system development process, source, biophysical-chemical properties, and associated biological pathways (especially via cell surface receptors) of native and fragmented HA. We also tried to address an overview of the potential role of HA (native HA vs fragments) in the modulation of inflammation, immune response and various cancer targeting delivery applications. This review will also highlight the HA based therapeutic systems, medical devices and future perspectives of various biomedical applications were discussed in detail.

7 August 2019 in Cells
Verified
Journal Article
Open access
PDF file
Srinivasa Reddy BonamSrinivasa Reddy Bonam
Srinivasa Reddy Bonam
MRMarc Ruff
Marc Ruff
Sylviane MullerSylviane Muller
Sylviane Muller
HSPA8/HSC70 is a molecular chaperone involved in a wide variety of cellular processes. It plays a crucial role in protein quality control, ensuring the correct folding and re-folding of selected proteins, and controlling the elimination of abnormally-folded conformers and of proteins daily produced in excess in our cells. HSPA8 is a crucial molecular regulator of chaperone-mediated autophagy, as a detector of substrates that will be processed by this specialized autophagy pathway. In this review, we shortly summarize its structure and overall functions, dissect its implication in immune disorders, and list the known pharmacological tools that modulate its functions. We also exemplify the interest of targeting HSPA8 to regulate pathological immune dysfunctions.

14 September 2022 in Science Translational Medicine
Verified
Journal Article
Open access
RHRenee L. Hajnik
Renee L. Hajnik
JPJessica Plante
Jessica Plante
YLYuejin Liang
Yuejin Liang
MAMohamad-Gabriel Alameh
Mohamad-Gabriel Alameh
Jinyi TangJinyi Tang
Jinyi Tang
HHHaitao Hu
Haitao Hu
Emergence of SARS-CoV-2 variants of concern (VOCs), including the highly transmissible Omicron and Delta strains, has posed constant challenges to the current COVID-19 vaccines that principally target the viral spike protein (S). Here, we report a nucleoside-modified messenger RNA (mRNA) vaccine that expresses the more conserved viral nucleoprotein (mRNA-N) and show that mRNA-N vaccination alone can induce modest control of SARS-CoV-2. Critically, combining mRNA-N with the clinically proven S-expressing mRNA vaccine (mRNA-S+N) induced robust protection against both Delta and Omicron variants. In the hamster models of SARS-CoV-2 VOC challenge, we demonstrated that, compared to mRNA-S alone, combination mRNA-S+N vaccination not only induced more robust control of the Delta and Omicron variants in the lungs but also provided enhanced protection in the upper respiratory tract. In vivo CD8 + T cell depletion suggested a potential role for CD8 + T cells in protection conferred by mRNA-S+N vaccination. Antigen-specific immune analyses indicated that N-specific immunity, as well as augmented S-specific immunity, was associated with enhanced protection elicited by the combination mRNA vaccination. Our findings suggest that combined mRNA-S+N vaccination is an effective approach for promoting broad protection against SARS-CoV-2 variants.